Now Playing
Opinion|Videos|August 26, 2024
Epidemiology of C. difficile Infections in the US
A panel of experts provide an overview of the epidemiology of Clostridioides difficile infections, highlighting diagnostic practices and the role of antimicrobial stewardship.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How often do we see C. difficile infections (CDI) in the general population in the US?
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
3
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
4
Measles Update: October 30, 2026
5